I agree that this site is using cookies. You can find further informations here.
X
Vetter, Thorsten
75  results:
Search for persons X
?
1

Patient‐reported, observer‐reported and performance outcome..:

Silva, Marcio ; Moseley, Jane ; Vetter, Thorsten...
British Journal of Clinical Pharmacology.  90 (2023)  1 - p. 299-312 , 2023
Link: https://doi.org/10.1111/..
 
?
2

EMA-FDA Parallel Scientific Advice: Optimizing Development ..:

Thor, Shannon ; Vetter, Thorsten ; Marcal, Anabela.
Therapeutic Innovation & Regulatory Science.  57 (2023)  4 - p. 656-661 , 2023
Link: https://doi.org/10.1007/..
 
?
3

Evolving regulatory perspectives on digital health technolo..:

Colloud, Seya ; Metcalfe, Thomas ; Askin, Scott...
npj Digital Medicine.  6 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
4

Biomarker Qualification at the European Medicines Agency: A..:

Bakker, Elisabeth ; Hendrikse, Natalie M. ; Ehmann, Falk...
Clinical Pharmacology & Therapeutics.  112 (2022)  1 - p. 69-80 , 2022
Link: https://doi.org/10.1002/..
 
?
5

Biomarkers in Medicines Development—From Discovery to Regul..:

Hendrikse, Natalie M. ; Llinares Garcia, Jordi ; Vetter, Thorsten..
Frontiers in Medicine.  9 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
6

Perspectives on a Way Forward to Implementation of Precisio..:

Bakker, Elisabeth ; Mol, Peter G. M. ; Nabais, João...
Frontiers in Pharmacology.  12 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
7

Change in Albuminuria and Estimated GFR as End Points for C..:

Holtkamp, Frank ; Gudmundsdottir, Hrefna ; Maciulaitis, Romaldas...
American Journal of Kidney Diseases.  75 (2020)  1 - p. 6-8 , 2020
Link: https://doi.org/10.1053/..
 
?
8

Multistakeholder Advice at the European Medicines Agency: I..:

Vamvakas, Spiros ; Moseley, Jane ; Vetter, Thorsten
Clinical Pharmacology & Therapeutics.  105 (2019)  4 - p. 819-821 , 2019
Link: https://doi.org/10.1002/..
 
?
9

Marketing authorisation of orphan medicines in Europe from ..:

Hofer, Matthias P. ; Hedman, Hanna ; Mavris, Maria...
Drug Discovery Today.  23 (2018)  2 - p. 424-433 , 2018
Link: https://doi.org/10.1016/..
 
?
10

GFR Decline as an End Point for Clinical Trials in CKD: A V..:

Mol, Peter G.M. ; Maciulaitis, Romaldas ; Vetter, Thorsten
American Journal of Kidney Diseases.  64 (2014)  6 - p. 838-840 , 2014
Link: https://doi.org/10.1053/..
 
?
11

Adaptive clinical trial designs for European marketing auth..:

Elsäßer, Amelie ; Regnstrom, Jan ; Vetter, Thorsten...
Trials.  15 (2014)  1 - p. , 2014
Link: https://doi.org/10.1186/..
 
?
12

Formation of a Ternary Complex among NHERF1, β-Arrestin, an..:

Klenk, Christoph ; Vetter, Thorsten ; Zürn, Alexander...
Journal of Biological Chemistry.  285 (2010)  39 - p. 30355-30362 , 2010
Link: https://doi.org/10.1074/..
 
?
13

Reverse Engineering of Digital Measures: Inviting Patients ..:

Mueller, Arne ; Nam, Julian ; Ng, Wan Fai...
info:eu-repo/semantics/altIdentifier/doi/10.1159/000530413.  , 2023
Link: https://hdl.handle.net/2..
 
?
14

Reverse Engineering of Digital Measures: Inviting Patients ..:

Clay, Ieuan ; Peerenboom, Nele ; Connors, Dana E...
volume:7.  , 2023
Link: https://hdl.handle.net/1..
 
?
15

Reverse Engineering of Digital Measures: Inviting Patients ..:

Clay, Ieuan ; Peerenboom, Nele ; Connors, Dana E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189241/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
1-15